TearLab Corp. (NASDAQ:TEAR) has been given an average recommendation of “Buy” by the six brokerages that are currently covering the firm. Two analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $2.00.

A number of research analysts recently commented on the company. HC Wainwright set a $2.00 target price on TearLab Corp. and gave the company a “buy” rating in a research note on Tuesday, November 8th. Zacks Investment Research upgraded TearLab Corp. from a “sell” rating to a “hold” rating in a research note on Wednesday, October 19th. Rodman & Renshaw restated a “buy” rating and issued a $2.00 target price on shares of TearLab Corp. in a research note on Saturday, October 15th. Finally, Roth Capital lowered TearLab Corp. from a “buy” rating to a “neutral” rating in a research note on Thursday, August 4th.

Shares of TearLab Corp. (NASDAQ:TEAR) opened at 0.5795 on Friday. TearLab Corp. has a 52 week low of $0.51 and a 52 week high of $1.75. The company’s 50 day moving average is $0.61 and its 200-day moving average is $0.70. The company’s market capitalization is $31.06 million.

TearLab Corp. (NASDAQ:TEAR) last issued its quarterly earnings results on Monday, November 7th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. The business had revenue of $20.90 million for the quarter, compared to analyst estimates of $7.13 million. During the same quarter last year, the firm earned ($0.24) earnings per share. The firm’s quarterly revenue was up 9.1% compared to the same quarter last year. On average, analysts expect that TearLab Corp. will post ($0.44) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Brokerages Set TearLab Corp. (TEAR) Target Price at $2.00” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this piece can be read at https://www.thecerbatgem.com/2016/11/28/brokerages-set-tearlab-corp-tear-target-price-at-2-00.html.

A number of hedge funds have recently made changes to their positions in the stock. AWM Investment Company Inc. bought a new stake in shares of TearLab Corp. during the second quarter worth $3,377,000. Sabby Management LLC bought a new stake in shares of TearLab Corp. during the second quarter worth $1,205,000. Perkins Capital Management Inc. boosted its stake in shares of TearLab Corp. by 5.3% in the third quarter. Perkins Capital Management Inc. now owns 1,848,242 shares of the company’s stock worth $1,201,000 after buying an additional 93,000 shares during the period. First Light Asset Management LLC boosted its stake in shares of TearLab Corp. by 0.4% in the second quarter. First Light Asset Management LLC now owns 3,760,430 shares of the company’s stock worth $2,407,000 after buying an additional 14,267 shares during the period. Finally, Vanguard Group Inc. boosted its stake in shares of TearLab Corp. by 0.4% in the second quarter. Vanguard Group Inc. now owns 825,984 shares of the company’s stock worth $528,000 after buying an additional 3,100 shares during the period. Hedge funds and other institutional investors own 38.14% of the company’s stock.

About TearLab Corp.

TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc, develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care.

5 Day Chart for NASDAQ:TEAR

Receive News & Stock Ratings for TearLab Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TearLab Corp. and related stocks with our FREE daily email newsletter.